Investor Presentaiton
Cardiovascular
milvexian
Camzyos
MYK-224
SSP data provides proof-of-concept in ACS
Acute Coronary Syndrome Unmet Need
Risk of recurrent CV events remains high despite dual antiplatelet therapy (5-10% annually) 1,2
Current treatments (antiplatelets & anticoagulants) decrease CV events, but increase risk of major bleeding
900K³ patients diagnosed in the U.S.
Scientific rationale for milvexian in ACS
Ischemic stroke and ACS
share similar underlying
pathophysiology and
treatment
ooo
FXa on top of
dual antiplatelet shows
efficacy but with
excess bleeding
In AXIOMATIC-SSP, milvexian
demonstrated efficacy in reducing
recurrent ischemic stroke with no
increase in severe bleeding vs. placebo.
Phase 3 study in ACS underway
Ill Bristol Myers Squibb™
1. Steg G, et al. JAMA. 2007. 2. Sorbets E, et al. J Eur Heart J. 2020. 3. Decision Resources Group, BMS Internal Analysis
Not for Product Promotional Use 117View entire presentation